ArticleDiscover oncology2026
FSCN1 drives sarcoma progression and immunosuppression revealed by pan-cancer analysis and functional assays.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundSarcoma accounts for less than 1% of human malignancies but is a highly aggressive and heterogeneous group of tumors originating from mesenchymal tissues. Current treatments yield unsatisfactory results due to unclear progression mechanisms, highlighting the need for novel biomarkers for treatment efficacy and prognosis prediction. FSCN1 is an actin-bundling protein that localizes to the core actin bundles within microvillar projections and filopodial extensions in migrating cells. This study aims to investigate the role of FSCN1 in pan-cancer, with a particular focus on sarcoma, by conducting comprehensive bioinformatics analysis.
methodsWe analyzed FSCN1’s pan-cancer expression, epigenetic status, and genetic alterations. FSCN1 expression in tumor and normal tissues was assessed using multiple databases. Its association with pathological stages was analyzed, and prognostic and diagnostic values were evaluated via TCGA data and ROC curves. Genetic alterations, DNA methylation, and mRNA modifications were studied using relevant tools. The FSCN1- lncRNA-miRNA regulatory network was constructed in sarcoma, and co-expressed gene functional analysis was also carried out.
resultsOur findings demonstrate that FSCN1 is frequently upregulated across a broad spectrum of human cancers. Elevated FSCN1 expression correlates with unfavorable overall survival in multiple cancer types and exhibits robust diagnostic performance in pan-cancer cohorts, with particular prominence in sarcoma. The FSCN1 promoter region displays hypomethylation in sarcoma, and its transcript levels are positively associated with mRNA modification signatures. We constructed a competing endogenous RNA (ceRNA) network encompassing FSCN1, lncRNAs, and miRNAs, and identified critical miRNA-FSCN1 interactions. Functional enrichment analysis of FSCN1 co-expressed genes uncovered key biological pathways. Immunohistochemical validation confirmed FSCN1 protein overexpression in selected sarcoma tissue specimens.
conclusionsFSCN1 is a potential biomarker for the diagnosis, prognosis, and prediction of treatment response in sarcoma, and is involved in sarcoma progression through multiple mechanisms, providing insights for targeted sarcoma therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.